Share This Author
Response criteria for phase II studies of supratentorial malignant glioma.
- D. Macdonald, T. Cascino, S. Schold, J. Cairncross
- MedicineJournal of Clinical Oncology
- 1 July 1990
This work suggests "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications, to minimize misinterpretations of response.
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
- H. Brem, S. Piantadosi, S. Schold
- MedicineThe Lancet
- 22 April 1995
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
- L. Deangelis, W. Seiferheld, S. Schold, B. Fisher, C. Schultz
- MedicineJournal of Clinical Oncology
- 15 December 2002
This is the first multicenter trial demonstrating improved survival with the combination of chemotherapy plus RT compared with previous reports of RT alone, and high-dose methotrexate combined with cranial irradiation is an effective therapeutic approach to PCNSL, but neurotoxicity is a delayed risk of this approach.
Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer
- F. A. Luque, H. Furneaux, J. Posner
- Medicine, BiologyAnnals of neurology
- 1 March 1991
The presence of anti‐Ri antibody identifies a subset of patients with paraneoplastic ataxia and eye movement disorders (opsoclonus) who usually suffer from breast or other gynecological cancer; the antibody when present is a useful marker for an underlying malignancy.
Increasing incidence of primary brain lymphoma in the US
- N. Eby, S. Grufferman, Christina M. Flannelly, S. Schold, F. Vogel, P. Burger
- MedicineCancer
- 1 December 1988
The increased incidence of primary brain lymphoma in the US appears to be real: It antedates the AIDS epidemic and does not appear to be related to organ transplantation, another cause of increased risk of brain lymph cancer.
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
- H. Brem, M. Mahaley, J. Cozzens
- MedicineJournal of neurosurgery
- 1 March 1991
In this Phase I-II study, 21 patients with recurrent malignant glioma were treated with BCNU released interstitially by means of a polyanhydride biodegradable polymer implant, which was well tolerated at all three levels.
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.
- K. Jaeckle, H. Eyre, S. Schold
- MedicineJournal of Clinical Oncology
- 1 October 1998
The MGMT level in tumor tissue specimens may be a predictive marker of survival in patients with malignant astrocytoma that is independent of other known prognostic factors (age, performance status, histology).
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.
This study demonstrates that high-dose tamoxifen can be safely administered and that plasma concentrations that may inhibit P-glycoprotein function can be achieved, and recommends this dose for phase II trials of tamoxIFen to modulate P- Glycoprotein-mediated drug resistance.
Multifaceted resistance of gliomas to temozolomide.
- D. Bocangel, S. Finkelstein, S. Schold, K. Bhakat, S. Mitra, D. Kokkinakis
- Medicine, BiologyClinical cancer research : an official journal of…
- 1 August 2002
By testing a limited number of glial tumors in cell culture and also as xenografts, it is shown that mobilization of the p53 in response to TMZ damage is likely to induce a cell cycle arrest and apoptosis inglial tumors.
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
- H. Okada, F. Lieberman, I. Pollack
- Medicine, BiologyJournal of Translational Medicine
- 19 December 2007
Feasibility challenges inherent in the generation of a patient-specific gene transfection-based vaccine strongly suggests the need for more practical formulations that would allow for the timely administration of vaccines.
...
...